Researchers from The George Institute for Global Health are trying to find out if cholestrol lowering medication (Statin), can help reduce ongoing neurological symptoms such as problems with memory and concentration, mood disturbances, fatigue and, muscle weakness, after Covid19 infection (Long Covid).

Study description/purpose

Have you tested positive for COVID-19 in the past 12 months?

Are you still experiencing:
• Memory problems?
• Sleep disturbance or fatigue?
• Difficulty focusing?
• Increased anxiety?
• Low mood?
• Other neurological symptoms?

If so, we would like to invite you to participate in the STRONGER study – Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy.

This is an exciting international ‘long-COVID’ study run by The George Institute for Global Health. We will test if a statin medication, approved for use in lowering cholesterol, can help reduce ongoing neurological symptoms such as problems with memory and concentration, mood disturbances, fatigue and muscle weakness.

We are seeking adult participants who have tested positive for COVID-19 who have any ongoing neurological symptoms (listed above).

What’s Involved?

This study will involve taking a statin medication once a day for 18 months and attending 6 study visits in total (in-person clinic visit and/or telephone consultations) in this time.

Study sites are located at Brain and Mind Centre (Sydney) and Monash University (Melbourne). Remote participation via tele-health/videoconference is available to those who cannot travel to the study site.

If you would like to learn more about this study, visit the study site today.

Recruitment criteria

You may be eligible to participate in this study if you:

  • Are aged ≥18 years
  • Have a history of COVID-19 that is confirmed by a positive Polymerase-Chain-Reaction (PCR) test, Rapid Antigen Test (RAT) or any other test.
  • Have any ongoing neurological symptoms as a result of COVID-19 (e.g. problems with memory, concentration, sleep disturbance and fatigue) that is identified through administration of the checklist of symptoms on the Somatic and Psychological Health Report (SPHERE) questionnaire, or reported current loss of smell (anosmia) as a result of COVID-19;
  • Are able to fully participate in all procedures, including cognitive assessments
  • Are able and willing to provide written informed consent


Participants will be reimbursed $100 at baseline and 18-month visits, with travel/parking costs reimbursed for clinic/pathology centre visits.

Study sponsor / funder

Research team contacts


Register your interest

    Please sign up on Join Us here
    You need to be registerd to deterime if you quilify for the study